Related Experiment Videos
[Basic studies on the 111In labeled antisense oligonucleotide for tumor imaging]
Y Fujibayashi1, K Nakagawa, A Waki
1Department of Radiopharmaceutical Chemistry, Biomedicaimaging Research Center, Fukui Medical School, Japan.
Abstract:
Antisense oligonucleotide labeled with short lived radionuclide has been proposed as a radiopharmaceutical for the detection of abnormal gene expression. In this study, plausibility of 32P or 111In labeled oligonucleotide was basically evaluated using c-erbB-2 protooncogene mRNA as a model target. In cell uptake studies, sequence specific accumulation of 32P-oligonucleotide was found in the cells with c-erbB-2 mRNA expression, but not control cells, indicating the basic possibility of antisense strategy. Synthesis of 111In labeled isothiocyanobenzyl-EDTA (IBE)-oligonucleotide could be performed, but some problems were found in purification step. Stability of 111In-IBE-oligonucleotide was high when compared with that of 32P-oligonucleotide, and in vivo biodistribution data might indicate that 111In-IBE-oligonucleotide was plausible for tumor imaging.
Insights
Antisense oligonucleotides labeled with radionuclides show potential for detecting abnormal gene expression. Studies confirm sequence-specific uptake in cells expressing the target gene, supporting the antisense strategy for diagnostic applications.
Area of Science:
- Molecular Biology
- Radiochemistry
- Oncology
Context:
- Antisense oligonucleotides (ASOs) are investigated as targeted radiopharmaceuticals.
- Detecting abnormal gene expression is crucial for diagnosing and monitoring diseases, particularly cancer.
- Short-lived radionuclides offer advantages for diagnostic imaging due to their decay properties.
Purpose:
- To evaluate the feasibility of using 32P or 111In-labeled oligonucleotides as radiopharmaceuticals.
- To assess the antisense strategy for detecting specific mRNA targets, using c-erbB-2 protooncogene mRNA as a model.
- To explore the potential of 111In-labeled oligonucleotides for in vivo tumor imaging.
Summary:
- Sequence-specific accumulation of 32P-labeled oligonucleotide was observed in cells expressing c-erbB-2 mRNA, validating the antisense approach.
- Synthesis of 111In-labeled isothiocyanobenzyl-EDTA (IBE)-oligonucleotide was achieved, though purification presented challenges.
- 111In-IBE-oligonucleotide demonstrated superior stability compared to 32P-oligonucleotide, with biodistribution data suggesting its potential for tumor imaging.
Impact:
- This research validates the fundamental possibility of using antisense oligonucleotides labeled with radionuclides for diagnostic purposes.
- The findings support the development of novel targeted radiopharmaceuticals for detecting aberrant gene expression in diseases like cancer.
- Further optimization of labeling and purification methods could lead to effective 111In-based ASO radiotracers for clinical imaging.